Powerful Formulation for Respiratory Infection Prevention and Treatment

Description

This technology is a set of innovative pharmaceutical formulations that utilize metabolites derived from specific gut microbiota to prevent respiratory infections and enhance immune health. Formulations are available for both oral and intranasal administration, offering flexibility and ease of use. By strengthening the immune system's foundational response, this formulation has great potential to reduce the severity of infections and the risk of related health complications in the elderly and immunocompromised populations. In preclinical studies, this formulation demonstrated protection against influenza respiratory infections in mice.

In 2021, the CDC reported 142,342 deaths from chronic lower respiratory disease in the U.S. alone, highlighting the urgent need for effective prevention and treatment solutions. Globally, over 545 million people were living with chronic respiratory conditions as of 2017, which is a 39.8% increase since 1990. These trends highlight the importance of developing preventative interventions that support vulnerable populations.

Benefits

• Highly Effective: Shown to protect mice against influenza respiratory infections.
• Enhanced Mucociliary Clearance: Improves pathogen removal from the respiratory tract in mice.
• Minimizes Infection Severity: Specifically beneficial for high-risk groups, including the elderly and immunocompromised.
• Ease of Use: Available as a nasal spray or oral formulation for ease of use and rapid uptake.

Applications

• Chronic Respiratory Disease Prevention
• Seasonal Respiratory Protection
• Post-Infection Recovery

Patent Status

• Provisional application filed

Publications